Back to Journals » Journal of Asthma and Allergy » Volume 11

Anaphylaxis: getting to the point (and price) of diagnosis and treatment

Authors Moss RB

Received 10 April 2018

Accepted for publication 16 April 2018

Published 20 June 2018 Volume 2018:11 Pages 109—110

DOI https://doi.org/10.2147/JAA.S170650

Checked for plagiarism Yes

Editor who approved publication: Dr Luis Garcia-Marcos


Ronald B Moss

Adamis Pharmaceuticals Corporation, San Diego, CA, USA

Anaphylaxis was first described by Charles Richet and Paul Portier in 1901 as an immune reaction that is the opposite of immune protection resulting from vaccination.1 Anaphylaxis can be better categorized into both immunoglobulin E (IgE) and non-IgE pathways.2 Between 1.6% and 5.1% of the Americans are estimated to experience anaphylaxis, which can be fatal.3 The common triggers for an acute anaphylactic episode are foods, drugs, and venoms. Ultimately, a number of mediators are released that explain the clinical symptoms of flushing, pruritus, urticaria, shortness of breath, bronchospasm, hypotension, and cardiovascular collapse.2 Epinephrine injection is the evidence-based treatment for acute anaphylaxis, and delayed epinephrine administration is a risk factor for fatal anaphylaxis.3 However, like many other effective therapies in medicine, there remain barriers to treatment of anaphylaxis.
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]